1. Home
  2. INTS vs PIII Comparison

INTS vs PIII Comparison

Compare INTS & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • PIII
  • Stock Information
  • Founded
  • INTS 2012
  • PIII 2015
  • Country
  • INTS United States
  • PIII United States
  • Employees
  • INTS N/A
  • PIII N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • PIII Medical/Nursing Services
  • Sector
  • INTS Health Care
  • PIII Health Care
  • Exchange
  • INTS Nasdaq
  • PIII Nasdaq
  • Market Cap
  • INTS 33.4M
  • PIII 32.2M
  • IPO Year
  • INTS 2023
  • PIII N/A
  • Fundamental
  • Price
  • INTS $2.11
  • PIII $0.23
  • Analyst Decision
  • INTS Strong Buy
  • PIII Buy
  • Analyst Count
  • INTS 3
  • PIII 3
  • Target Price
  • INTS $8.50
  • PIII $2.38
  • AVG Volume (30 Days)
  • INTS 28.4K
  • PIII 1.2M
  • Earning Date
  • INTS 03-13-2025
  • PIII 03-27-2025
  • Dividend Yield
  • INTS N/A
  • PIII N/A
  • EPS Growth
  • INTS N/A
  • PIII N/A
  • EPS
  • INTS N/A
  • PIII N/A
  • Revenue
  • INTS N/A
  • PIII $1,476,630,000.00
  • Revenue This Year
  • INTS N/A
  • PIII $21.45
  • Revenue Next Year
  • INTS N/A
  • PIII N/A
  • P/E Ratio
  • INTS N/A
  • PIII N/A
  • Revenue Growth
  • INTS N/A
  • PIII 25.38
  • 52 Week Low
  • INTS $1.50
  • PIII $0.17
  • 52 Week High
  • INTS $5.94
  • PIII $1.20
  • Technical
  • Relative Strength Index (RSI)
  • INTS 41.98
  • PIII 60.20
  • Support Level
  • INTS $1.84
  • PIII $0.19
  • Resistance Level
  • INTS $2.53
  • PIII $0.25
  • Average True Range (ATR)
  • INTS 0.32
  • PIII 0.02
  • MACD
  • INTS -0.02
  • PIII 0.01
  • Stochastic Oscillator
  • INTS 37.50
  • PIII 75.64

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Share on Social Networks: